We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > cluster headache

News List

Lilly enlists patients to raise cluster headache awareness after Emgality scores second nod fiercepharma
June 28, 2019
Cluster headache pain is so intense, one patient describes banging his head against the refrigerator door to make it stop.
FDA ‘yes’ for Emgality in cluster headache pharmatimes
June 05, 2019
The US Food and Drug Administration (FDA) has announced the approval of the first treatment for episodic cluster headache that reduces the frequency of attacks, Eli Lilly’s Emgality (galcanezumab-gnlm).
Lilly submits New Drug Application to the FDA for lasmiditan for acute treatment of migraine, receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for prevention of episodic cluster headache worldpharmanews
November 17, 2018
The NDA for lasmiditan includes data from two Phase 3 single-attack studies (SAMURAI and SPARTAN), which evaluated the safety and efficacy of lasmiditan for the acute treatment of migraine.